Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.
During his long tenure at the agency, Pazdur implemented several initiatives to expedite oncology drug approvals. Credit: Tada Images/Shutterstock.com.
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week, leaders across the biopharma industry have shared their support for agency veteran Dr Richard Pazdur to take the role as the next commissioner.
Almost 400 biotech CEOS, investment partners, financial analysts, and patient advocates have signed a letter that recommends Pazdur be appointed the new FDA commissioner. Addressed to US President Donald Trump, the signatories state that Pazdur – who spent 26 years at the FDA – has the qualities to quell a period of unrest at the agency. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
